Company news
Fibrobiologics, Inc. (NASDAQ:FBLG) news
Every Fibrobiologics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
September 1, 2026
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
August 27, 2026
FibroBiologics Regains Compliance with Nasdaq Trading Rules
August 26, 2026
FibroBiologics Appoints Leigh Steinberg to Board of Directors
August 24, 2026
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
August 20, 2026
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
August 18, 2026
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
August 11, 2026
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
August 5, 2026
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
July 31, 2026
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
July 9, 2026
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
July 7, 2026
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 30, 2026
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
June 29, 2026
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
June 26, 2026
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
June 22, 2026
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
June 16, 2026
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
June 3, 2026
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology...
May 22, 2026
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
May 18, 2026
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
May 11, 2026
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing a...
May 4, 2026
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
May 4, 2026
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
April 30, 2026
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
April 30, 2026
FibroBiologics Compliant with All Nasdaq Listing Requirements
April 20, 2026
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
April 10, 2026
FibroBiologics Announces Closing of $3 Million Public Offering
April 2, 2026
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
March 31, 2026
FibroBiologics Announces Pricing of $3 Million Public Offering
March 31, 2026
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
March 25, 2026
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
March 12, 2026
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
March 5, 2026
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
March 2, 2026
FibroBiologics to Present at the BIO Investment & Growth Summit
February 26, 2026
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
February 24, 2026
FibroBiologics Granted Extension by Nasdaq to Regain Compliance
February 23, 2026
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
February 10, 2026
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
February 5, 2026
FibroBiologics to Present at the DealFlow Discovery Conference
January 20, 2026
FibroBiologics CEO Issues Letter to Shareholders
January 7, 2026
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
January 6, 2026
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerat...
January 5, 2026
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
December 31, 2025
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 16, 2025
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 15, 2025
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal ...
December 10, 2025
FibroBiologics Announces Payoff of Outstanding Debt
November 26, 2025
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 25, 2025
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 24, 2025
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
November 20, 2025